HROW vs. AVEO, KIN, LFVN, INDV, TGTX, RNA, JANX, ACAD, ARVN, and BHC
Should you be buying Harrow stock or one of its competitors? The main competitors of Harrow include AVEO Pharmaceuticals (AVEO), Kindred Biosciences (KIN), LifeVantage (LFVN), Indivior (INDV), TG Therapeutics (TGTX), Avidity Biosciences (RNA), Janux Therapeutics (JANX), ACADIA Pharmaceuticals (ACAD), Arvinas (ARVN), and Bausch Health Companies (BHC). These companies are all part of the "medical" sector.
AVEO Pharmaceuticals (NASDAQ:AVEO) and Harrow (NASDAQ:HROW) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, community ranking, analyst recommendations and institutional ownership.
AVEO Pharmaceuticals received 384 more outperform votes than Harrow when rated by MarketBeat users. Likewise, 69.72% of users gave AVEO Pharmaceuticals an outperform vote while only 56.25% of users gave Harrow an outperform vote.
In the previous week, Harrow had 6 more articles in the media than AVEO Pharmaceuticals. MarketBeat recorded 6 mentions for Harrow and 0 mentions for AVEO Pharmaceuticals. AVEO Pharmaceuticals' average media sentiment score of 1.10 beat Harrow's score of 0.25 indicating that Harrow is being referred to more favorably in the news media.
Harrow has higher revenue and earnings than AVEO Pharmaceuticals. Harrow is trading at a lower price-to-earnings ratio than AVEO Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Harrow has a consensus target price of $29.80, indicating a potential upside of 67.13%. Given AVEO Pharmaceuticals' higher possible upside, analysts clearly believe Harrow is more favorable than AVEO Pharmaceuticals.
50.0% of AVEO Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 3.3% of AVEO Pharmaceuticals shares are owned by company insiders. Comparatively, 13.7% of Harrow shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Harrow has a net margin of -22.59% compared to Harrow's net margin of -30.79%. AVEO Pharmaceuticals' return on equity of -39.82% beat Harrow's return on equity.
AVEO Pharmaceuticals has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.Comparatively, Harrow has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500.
Summary
Harrow beats AVEO Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
Get Harrow News Delivered to You Automatically
Sign up to receive the latest news and ratings for HROW and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HROW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
